1606 Corp. Files 8-K Report
Ticker: CBDW · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1877461
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
1606 Corp. filed an 8-K, check for updates.
AI Summary
On January 13, 2025, 1606 Corp. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that 1606 Corp. is making disclosures to the SEC, which could include important updates for investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate material financial information.
Key Players & Entities
- 1606 Corp. (company) — Registrant
- January 13, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- 000-56467 (identifier) — SEC File Number
- 86-1497346 (identifier) — I.R.S. Employer Identification Number
- 2425 E. Camelback Rd Suite 150 Phoenix , AZ 85016 (address) — Principal executive offices
- 602-481-1544 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the registrant is 1606 Corp.
On what date was this report filed?
The report was filed on January 13, 2025.
In which state was 1606 Corp. incorporated?
1606 Corp. was incorporated in Nevada.
What is the principal executive office address of 1606 Corp.?
The principal executive office address is 2425 E. Camelback Rd Suite 150 Phoenix, AZ 85016.
Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-13 06:03:28
Filing Documents
- onesix_8k.htm (8-K) — 26KB
- onesix_ex991.htm (EX-99.1) — 14KB
- 0001477932-25-000168.txt ( ) — 159KB
- cbdw-20250113.xsd (EX-101.SCH) — 6KB
- cbdw-20250113_lab.xml (EX-101.LAB) — 13KB
- cbdw-20250113_cal.xml (EX-101.CAL) — 1KB
- cbdw-20250113_pre.xml (EX-101.PRE) — 8KB
- cbdw-20250113_def.xml (EX-101.DEF) — 2KB
- onesix_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On January 13, 2025, 1606 Corp., a Nevada corporation (the "Company"), filed a press release which issued a statement of its strong support for strategic investment target, Adnexus Biotechnologies Inc., following its groundbreaking announcement of Trapicolast , a pioneering antimalarial drug developed through its innovative AI-powered Sutra platform. The furnishing of the press release is not an admission as to the materiality of any information therein. The information contained in the press release is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC") and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. The information in this Item 7.01 of this Current Report on Form 8-K and the press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 1606 Corp. Date: January 13, 2025 By: /s/ Austen Lambrecht Austen Lambrecht, Chief Executive Officer 3